Clinical effect study of low molecular weight heparin calcium in the treatment of chronic obstructive pulmonary disease combined with pulmonarv heart disease
10.3760/ema.j.issn.1673-4904.2012.10.009
- VernacularTitle:低分子量肝素钙辅助治疗在慢性阻塞性肺疾病伴发肺源性心脏病患者中的疗效研究
- Author:
Xiangpeng LI
;
Hao MENG
;
Liuliu XU
;
Liu ZHANG
- Publication Type:Journal Article
- Keywords:
Heparin,low molecular weight;
Pulmonary disease,chronic obstructive;
Pulmonary heart disease
- From:
Chinese Journal of Postgraduates of Medicine
2012;35(10):23-25
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical effect of low molecular weight heparin calcium in the treatment of chronic obstructive pulmonary disease combined with pulmonary heart disease.MethodsA total of 64 patients with chronic obstructive pulmonary disease combined with pulmonary heart disease from December 2008 to December 2010 were enrolled in this study and divided into treatment group and control group by random digits table with 32 cases each.The control group was given routine treatment and the treatment group was given low molecular weight heparin calcium for 7 days at the basis of routine treatment.ResultsThe total effective rate in treatment group[ 90.6％ (29/32) ] was significantly higher than that in control group [ 68.8％ (22/32) ] (P ＜ 0.05 ).In treatment group,the levels of arterial carbon dioxide tension (PaCO2) and arterial oxygen tension (PaO2) after treatment [(54.64±9.63),(74.21 ± 11.76) mm Hg (1 mm Hg =0.133 kPa)] were significantly decreased compared with before treatment [(78.66 ± 11.22),(53.42 ± 8.84 ) mm Hg ] (P ＜ 0.01 ).In control group,the levels of PaCO2 and PaO2 after treatment [ (61.10 ±7.24),(65.07 ± 8.21 ) mm Hg] were significantly decreased compared with before treatment[ (79.52 ± 12.54),(51.35 ± 7.31 ) mm Hg ] (P ＜ 0.05 ).After treatment the levels of PaCO2 and PaO2 in treatment group were better than those in control group (P ＜ 0.05).ConclusionsThe low molecular weight heparin calcium in treatment of chronic obstructive pulmonary disease combined with pulmonary heart disease can effectively improve the clinical manifestation.It is worth the clinical promoted application.
